A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib

Trial Profile

A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Alpelisib (Primary) ; Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 12 Sep 2017 Planned End Date changed from 1 Jul 2017 to 28 Dec 2018.
    • 12 Sep 2017 Planned primary completion date changed from 1 Jul 2017 to 28 Dec 2018.
    • 13 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top